The evolving role of cytotoxic chemotherapy in the management of patients with metastatic prostate cancer.

@article{Diamond2015TheER,
  title={The evolving role of cytotoxic chemotherapy in the management of patients with metastatic prostate cancer.},
  author={Elan Diamond and Mar{\'i}a del Carmen Garcias and Beerinder S Karir and Scott T Tagawa},
  journal={Current treatment options in oncology},
  year={2015},
  volume={16 2},
  pages={9}
}
Prostate cancer (PC) is the most common cancer in men in the United States. Although outcomes are excellent for early-stage disease, survival for men with metastatic PC is limited. While older studies did not supported the use of chemotherapy in PC, the efficacy of taxane chemotherapy plus prednisone is now well established in men with metastatic castration resistant PC (CRPC). The results of CHAARTED trial have further expanded the use of chemotherapy to patients with metastatic hormone… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 82 references

Docetaxelestramustine in localized high-risk prostate cancer: Results of the French Genitourinary Tumor Group GETUG 12 phase III trial

  • K Fizazi, A Laplanche, F Lesaunier, R. Delva
  • J Clin Oncol
  • 2014

Evaluating the safety of abiraterone acetate (AA) and docetaxel (D) administered in combination in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC)

  • S Tagawa, D Nanus, E Posadas
  • J Clin Oncol
  • 2014

Similar Papers

Loading similar papers…